Efficacy Evaluation of Argatroban Combined with Edaravone in the Treatment of Cerebral Embolism Complicating with Atrial Fibrillation

OBJECTIVE: To evaluate the effectiveness and safety of argatroban combined with edaravone in the treatment of neurological deficits in patients with cerebral embolism complicating with atrial fibrillation. METHODS: 120 patients with cerebral embolism complicating with atrial fibrillation were randomly divided into two groups. Trial group was treated with agatroban combined with edaravone and control group was treated with low molecular heparin. The coagulative functions of two groups were determined before and after treatment. The degrees of neurological deficits were compared between two groups using NIHSS scoring and the rehabilitation condition was evaluated by Barthel index. The effectiveness of clinical treatment was analyzed statistically. RESULTS: There were no significant difference in coagulation index and NIHSS scoring between two groups before treatment (P0.05). The NIHSS scoring of trial group was improved significantly, compared with control group (P0.05). The coagulation time of trial group was prolonged, compared with control group (P0.05). The effective rates of trial group and control group were 91.38% and 70.17% (P0.01). The incidence rates of bleeding were 3.33% and 5.00% (P0.05). CONCLUSION: Early treatment of argatroban combined with edaravone is effective in the treatment of cerebral embolism complicating with atrial fibrillation.